These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. Lusingu J; Olotu A; Leach A; Lievens M; Vekemans J; Olivier A; Benns S; Olomi R; Msham S; Lang T; Gould J; Hallez K; Guerra Y; Njuguna P; Awuondo KO; Malabeja A; Abdul O; Gesase S; Dekker D; Malle L; Ismael S; Mturi N; Drakeley CJ; Savarese B; Villafana T; Ballou WR; Cohen J; Riley EM; Lemnge MM; Marsh K; Bejon P; von Seidlein L PLoS One; 2010 Nov; 5(11):e14090. PubMed ID: 21124768 [TBL] [Abstract][Full Text] [Related]
3. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022. Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519 [TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F; Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538 [TBL] [Abstract][Full Text] [Related]
6. Impact of social media news on COVID-19 vaccine hesitancy and vaccination behavior. Zhang Q; Zhang R; Wu W; Liu Y; Zhou Y Telemat Inform; 2023 May; 80():101983. PubMed ID: 37122766 [TBL] [Abstract][Full Text] [Related]
8. Overview of U.S. COVID-19 vaccine safety surveillance systems. Gee J; Shimabukuro TT; Su JR; Shay D; Ryan M; Basavaraju SV; Broder KR; Clark M; Buddy Creech C; Cunningham F; Goddard K; Guy H; Edwards KM; Forshee R; Hamburger T; Hause AM; Klein NP; Kracalik I; Lamer C; Loran DA; McNeil MM; Montgomery J; Moro P; Myers TR; Olson C; Oster ME; Sharma AJ; Schupbach R; Weintraub E; Whitehead B; Anderson S Vaccine; 2024 Apr; ():. PubMed ID: 38631952 [TBL] [Abstract][Full Text] [Related]
9. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Sacarlal J; Aponte JJ; Aide P; Mandomando I; Bassat Q; Guinovart C; Leach A; Milman J; Macete E; Espasa M; Ofori-Anyinam O; Thonnard J; Corachan S; Dubois MC; Lievens M; Dubovsky F; Ballou WR; Cohen J; Alonso PL Vaccine; 2008 Jan; 26(2):174-84. PubMed ID: 18069097 [TBL] [Abstract][Full Text] [Related]
10. Formal training in vaccine safety to address parental concerns not routinely conducted in U.S. pediatric residency programs. Williams SE; Swan R Vaccine; 2014 May; 32(26):3175-8. PubMed ID: 24731808 [TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Clark HF; Burke CJ; Volkin DB; Offit P; Ward RL; Bresee JS; Dennehy P; Gooch WM; Malacaman E; Matson D; Walter E; Watson B; Krah DL; Dallas MJ; Schödel F; Kaplan kM; Heaton P Pediatr Infect Dis J; 2003 Oct; 22(10):914-20. PubMed ID: 14551493 [TBL] [Abstract][Full Text] [Related]
12. Political Ideology and Trust in Government to Ensure Vaccine Safety: Using a U.S. Survey to Explore the Role of Political Trust. Lim J; Moon KK Int J Environ Res Public Health; 2023 Mar; 20(5):. PubMed ID: 36901469 [TBL] [Abstract][Full Text] [Related]
13. Safety profile of a replication-deficient human adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle. Barrera J; Brake DA; Kamicker BJ; Purcell C; Kaptur R; Schieber T; Lechtenberg K; Miller TD; Ettyreddy D; Brough DE; Butman BT; Colby M; Neilan JG Transbound Emerg Dis; 2018 Apr; 65(2):447-455. PubMed ID: 29076657 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the Euvichol-S oral cholera vaccine for prevention of Vibrio cholerae O1 infection in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial. Song KR; Chapagain RH; Tamrakar D; Shrestha R; Kanodia P; Chaudhary S; Wartel TA; Yang JS; Kim DR; Lee J; Park EL; Cho H; Lee J; Thaisrivichai P; Vemula S; Kim BM; Gupta B; Saluja T; Pansuriya RK; Ganapathy R; Baik YO; Lee YJ; Jeon S; Park Y; Her HL; Park Y; Lynch JA Lancet Glob Health; 2024 May; 12(5):e826-e837. PubMed ID: 38614631 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lazarus R; Querton B; Corbic Ramljak I; Dewasthaly S; Jaramillo JC; Dubischar K; Krammer M; Weisova P; Hochreiter R; Eder-Lingelbach S; Taucher C; Finn A; Lancet Infect Dis; 2022 Dec; 22(12):1716-1727. PubMed ID: 36075233 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study. Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood. Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccine safety inquiries to the centers for disease control and prevention immunization safety office. Miller ER; Moro PL; Shimabukuro TT; Carlock G; Davis SN; Freeborn EM; Roberts AL; Gee J; Taylor AW; Gallego R; Suragh T; Su JR Vaccine; 2023 Jun; 41(27):3960-3963. PubMed ID: 37248099 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial. Zhang L; Gao F; Zeng G; Yang H; Zhu T; Yang S; Meng X; Mao Q; Liu X J Pediatric Infect Dis Soc; 2021 Apr; 10(4):440-447. PubMed ID: 33269798 [TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Koch T; Dahlke C; Fathi A; Kupke A; Krähling V; Okba NMA; Halwe S; Rohde C; Eickmann M; Volz A; Hesterkamp T; Jambrecina A; Borregaard S; Ly ML; Zinser ME; Bartels E; Poetsch JSH; Neumann R; Fux R; Schmiedel S; Lohse AW; Haagmans BL; Sutter G; Becker S; Addo MM Lancet Infect Dis; 2020 Jul; 20(7):827-838. PubMed ID: 32325037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]